文献速递心境障碍精神分裂症与精神病性障碍睡眠障碍

大型多祖先生物样本库中与神经发育障碍相关拷贝数变异的临床特征分析

Clinical Characterization of Copy Number Variants Associated With Neurodevelopmental Disorders in a Large-scale Multiancestry Biobank.
PubMed 文献 · JAMA Psychiatry · 2022-01-01

研究在BioMe生物样本库24877名多祖先参与者中识别神经发育障碍相关拷贝数变异(NDD CNVs),患病率为2.5%。NDD CNVs富集于先天性疾病(OR 2.0)和重度抑郁症(OR 1.5),并与高血压、肾衰竭、阻塞性睡眠呼吸暂停、病态肥胖及体质指数升高相关,而与36项常见血清检测无关联。

要点

  • 24877名参与者中64种NDD CNVs总患病率为2.5%(n=627)。
  • NDD CNVs与先天性疾病(OR 2.0)和重度抑郁症(OR 1.5)富集相关。
  • NDD CNVs与高血压、肾衰竭、阻塞性睡眠呼吸暂停、病态肥胖及体质指数升高相关。

核心结论

  • 在大型多祖先生物样本库中阐明了携带NDD CNVs个体的临床特征,发现先天性疾病和重度抑郁症富集,并与高血压、肾衰竭、肥胖及肥胖相关表型(阻塞性睡眠呼吸暂停和体质指数升高)相关。
  • NDD CNVs与肥胖结局的关联提示其可能具有超出既往报道神经发育结局的多效性。
  • 未来临床遗传学研究可能有助于识别高危个体及针对特定遗传变异的治疗策略。

研究设计与样本

  • 研究基于纽约西奈山卫生系统电子健康记录链接的BioMe生物样本库,纳入自2007年9月起招募的24877名多祖先参与者,分析2004年5月至2019年5月的电子健康记录数据。
  • NDD CNVs通过全外显子组测序和基因型阵列数据的两种拷贝数变异识别算法共识确定,并进行新型计算机模拟临床评估。
  • 研究进行了一系列表型富集和关联分析。
  • 24877名参与者中,14586名(58.7%)为女性;自我报告的祖先类别包括5965名(24.0%)非洲祖先、7892名(31.7%)欧洲祖先和8536名(34.3%)西班牙裔祖先;平均(SD)年龄为50.5(17.3)岁。

主要发现

  • 24877名个体中,64种NDD CNVs的患病率为2.5%(n=627),患病率随位点变化,证实存在某些相对高流行的NDD CNVs(如15q11.2缺失/重复)。
  • NDD CNVs聚合集富集于先天性疾病(OR 2.0;95%CI 1.1-3.5;P=.01)和重度抑郁症(OR 1.5;95%CI 1.1-2.0;P=.01)。
  • 在医学诊断的荟萃分析(n=195个层次聚类诊断代码)中,NDD CNVs与多种医学结局显著相关,包括原发性高血压(z=3.6;P=2.8×10⁻⁴)、肾衰竭(z=3.3;P=1.1×10⁻³)和阻塞性睡眠呼吸暂停(z=3.4;P=8.1×10⁻⁴),另一分析中与病态肥胖相关(z=3.8;P=1.3×10⁻⁴)。
  • NDD CNVs在多祖先分析中与体质指数升高相关(β=0.19;95%CI 0.10-0.31;P=.003)。
  • 对于36项常见血清检测,未发现与NDD CNVs的关联。

关键数值与推荐

  • NDD CNVs总患病率2.5%(n=627/24877)。
  • 先天性疾病富集OR 2.0(95%CI 1.1-3.5;P=.01)。
  • 重度抑郁症富集OR 1.5(95%CI 1.1-2.0;P=.01)。
  • 原发性高血压z=3.6(P=2.8×10⁻⁴);肾衰竭z=3.3(P=1.1×10⁻³);阻塞性睡眠呼吸暂停z=3.4(P=8.1×10⁻⁴);病态肥胖z=3.8(P=1.3×10⁻⁴)。
  • 体质指数升高β=0.19(95%CI 0.10-0.31;P=.003)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Past studies identified rare copy number variants (CNVs) as risk factors for neurodevelopmental disorders (NDDs), including autism spectrum disorder and schizophrenia. However, the clinical characterization of NDD CNVs is understudied in population cohorts unselected for neuropsychiatric disorders and in cohorts of diverse ancestry. OBJECTIVE: To identify individuals harboring NDD CNVs in a multiancestry biobank and to query their enrichment for select neuropsychiatric disorders as well as association with multiple medical disorders. DESIGN, SETTINGS, AND PARTICIPANTS: In a series of phenotypic enrichment and association analyses, NDD CNVs were clinically characterized among 24 877 participants in the BioMe biobank, an electronic health record-linked biobank derived from the Mount Sinai Health System, New York, New York. Participants were recruited into the biobank since September 2007 across diverse ancestry and medical and neuropsychiatric specialties. For the current analyses, electronic health record data were analyzed from May 2004 through May 2019. MAIN OUTCOMES AND MEASURES: NDD CNVs were identified using a consensus of 2 CNV calling algorithms, based on whole-exome sequencing and genotype array data, followed by novel in-silico clinical assessments. RESULTS: Of 24 877 participants, 14 586 (58.7%) were female; self-reported ancestry categories included 5965 (24.0%) who were of African ancestry, 7892 (31.7%) who were of European ancestry, and 8536 (34.3%) who were of Hispanic ancestry; and the mean (SD) age was 50.5 (17.3) years. Among 24 877 individuals, the prevalence of 64 NDD CNVs was 2.5% (n = 627), with prevalence varying by locus, corroborating the presence of some relatively highly prevalent NDD CNVs (eg, 15q11.2 deletion/duplication). An aggregate set of NDD CNVs were enriched for congenital disorders (odds ratio, 2.0; 95% CI, 1.1-3.5; P = .01) and major depressive disorder (odds ratio, 1.5; 95% CI, 1.1-2.0; P = .01). In a meta-analysis of medical diagnoses (n = 195 hierarchically clustered diagnostic codes), NDD CNVs were significantly associated with several medical outcomes, including essential hypertension (z score = 3.6; P = 2.8 × 10-4), kidney failure (z score = 3.3; P = 1.1 × 10-3), and obstructive sleep apnea (z score = 3.4; P = 8.1 × 10-4) and, in another analysis, morbid obesity (z score = 3.8; P = 1.3 × 10-4). Further, NDD CNVs were associated with increased body mass index in a multiancestry analysis (β = 0.19; 95% CI, 0.10-0.31; P = .003). For 36 common serum tests, there was no association with NDD CNVs. CONCLUSIONS AND RELEVANCE: Clinical features of individuals harboring NDD CNVs were elucidated in a large-scale, multiancestry biobank, identifying enrichments for congenital disorders and major depressive disorder as well as associations with several medical outcomes, including hypertension, kidney failure, and obesity and obesity-related phenotypes, specifically obstructive sleep apnea and increased body mass index. The association between NDD CNVs and obesity outcomes indicate further potential pleiotropy of NDD CNVs beyond neurodevelopmental outcomes previously reported. Future clinical genetic investigations may lead to insights of at-risk individuals and therapeutic strategies targeting specific genetic variants. The importance of diverse inclusion within biobanks and considering the effect of rare genetic variants in a multiancestry context is evident.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Birnbaum R, Mahjani B, Loos RJF, et al. Clinical Characterization of Copy Number Variants Associated With Neurodevelopmental Disorders in a Large-scale Multiancestry Biobank. JAMA Psychiatry. 2022. PMID: 35080590. doi:10.1001/jamapsychiatry.2021.4080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。